1. Research
2. Maternal paracetamol ...
3. Maternal paracetamol (acetaminophen) use during pregnancy and risk of autism spectrum disorder and attention deficit/hyperactivity disorder in offspring: umbrella review of systematic reviews

CCBYNC Open access

Research BMJ 2025; 391 doi: https://doi.org/10.1136/bmj-2025-088141 (Published 10 November 2025) Cite this as: BMJ 2025;391:e088141

1. Jameela Sheikh, doctoral student1,

2. John Allotey, professor1,

3. Soha Sobhy, associate professor2,

4. Maria Nieves Plana, clinical epidemiologist34,

5. Hilario Martinez-Barros, pharmacist34,

6. Harshitha Naidu, medical student2,

7. Fatima Junaid, resident physician2,

8. Reecha Sofat, professor5,

9. Ben W Mol, professor6,

10. Louise C Kenny, professor7,

11. Melissa Gladstone, professor1,

12. Helena Teede, professor8,

13. Javier Zamora, professor134,

14. Shakila Thangaratinam, professor1910

15. 1Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK

16. 2Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

17. 3Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

18. 4Consorcio de Investigación Biomédica en Red, CIBERESP, Madrid, Spain

19. 5Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

20. 6Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia

21. 7Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK

22. 8Monash Centre for Health Research and Implementation, Monash University, Melbourne, Australia

23. 9Liverpool Women’s NHS Foundation Trust, Liverpool, UK

24. 10NIHR North West Coast Applied Research Collaboration, UK

25. Correspondence to: S Thangaratinam s.thangaratinam{at}liverpool.ac.uk

• Accepted 4 November 2025

Abstract

Objective To assess the quality, biases, and validity of evidence on maternal paracetamol (acetaminophen) use during pregnancy and the risk of autism spectrum disorder (referred to as autism) and attention deficit/hyperactivity disorder (ADHD) in offspring.

Design Umbrella review of systematic reviews.

Data sources Medline, Embase, PsycINFO, and the Cochrane Database of Systematic Reviews, along with grey literature, Epistemonikos, and the reference lists of included studies (inception to 30 September 2025).

Inclusion criteria Systematic reviews of randomised trials and cohort, case-control, or cross sectional studies that reported maternal paracetamol use during pregnancy and the diagnosis of autism or ADHD in offspring. Details of the primary studies included in the reviews are reported, including adjustments for key confounders (maternal characteristics, indication for paracetamol use, and familial factors) and unmeasured confounders and ascertainment of outcomes.

Results Nine reviews (40 studies) reporting on autism (six studies) and ADHD (17 studies) in offspring were included. Four reviews undertook meta-analysis. The overlap of primary studies included in the reviews was very high (corrected covered area 23%). The reviews reported a possible to strong association between maternal paracetamol intake and autism or ADHD or both in offspring. Seven of the nine reviews advised caution when interpreting the findings owing to the potential risk of bias and confounding in the included studies. Confidence in the findings of the reviews was low (two reviews) to critically low (seven reviews) based on the AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews) criteria. Only one review included studies (n=2) reporting autism and ADHD in offspring that appropriately adjusted for familial factors and unmeasured confounding through sibling controlled analyses. In both studies, the increased risk of autism in offspring (one study, hazard ratio 1.05, 95% confidence interval 1.02 to 1.08) and ADHD (two studies, 1.07, 1.05 to 1.10 and 2.02, 1.17 to 3.25 ) observed in the whole cohort analyses did not persist in sibling controlled analyses for autism (0.98, 0.93 to 1.04) and ADHD (0.98, 0.94 to 1.02 and 1.06, 0.51 to 2.05).

Conclusion Existing evidence does not clearly link maternal paracetamol use during pregnancy with autism or ADHD in offspring.

Systematic review registration PROSPERO CRD420251154052.

Introduction

Paracetamol (acetaminophen) is one of the most commonly used drugs in pregnancy worldwide.12 It is the recommended treatment for pain relief and fever in pregnancy.34 In September 2025, the US president advised against using Tylenol (acetaminophen) during pregnancy, citing risks of autism in children exposed to the drug in utero.5 The announcement caused considerable concern among pregnant women and mothers of children with autism.6 Withholding paracetamol use for high fever risks poor pregnancy outcomes.789 Worldwide, regulatory health agencies and expert bodies, such as the UK’s Medicines and Healthcare Products Regulatory Agency, the European Medicines Agency, and the Australian Therapeutic Goods Administration, responded with reassurance about the safety of paracetamol use during pregnancy.101112 Professional bodies and health organisations advised women to contact their healthcare practitioners for evidence based information on the safety of maternal paracetamol use during pregnancy.1314

To date, numerous systematic reviews have synthesised the evidence on the risks of prenatal exposure to maternal paracetamol use and autism spectrum disorder (referred to as autism) and attention deficit/hyperactivity disorder (ADHD) in childhood.151617 These reviews, based on observational studies, vary in methodological quality, findings, and the interpretation of evidence.16 Primary studies that do not adjust for key confounders such as familial genetic and environmental factors, maternal health, indications for paracetamol use, and potential unmeasured confounders cannot accurately estimate the effects of in utero exposure to paracetamol on neurodevelopment in children.18 Erroneous conclusions could arise from ignoring the biases in primary studies and from inadequate definition and ascertainment of exposures and outcomes.1920 Given the heterogeneous quality and reporting of studies, a robust overview of existing evidence is urgently needed to guide healthcare professionals, women, and families in interpreting the risks of paracetamol use during pregnancy.21 We therefore conducted an umbrella review of systematic reviews to assess the overall quality and validity of existing evidence and the strength of association between paracetamol use during pregnancy and the risks of autism and ADHD in offspring.

Methods

Literature search and study selection

Our umbrella review is based on a prospective protocol (registered on PROSPERO, 26 September 2025) and follows the recommended methods for rapid reviews.22 Our findings are reported in line with the Preferred Reporting Items for Overviews of Reviews guidelines (see supplementary appendix 1).23 We searched Medline, Embase, PsycINFO, the Cochrane Database of Systematic Reviews, grey literature, and Epistemonikos from inception to 30 September 2025 for systematic reviews and meta-analyses of studies reporting maternal paracetamol use and autism spectrum disorder and ADHD outcomes. The search terms “paracetamol” or “acetaminophen” were combined with “pregnancy”, “antenatal”, or “maternal” that represented the population, which were further combined with terms for the outcome such as “child development”, “developmental disabilities”, “neurodevelopment”, “learning disorders”, “autism spectrum”, “attention deficit”, and “ADHD” (see supplementary appendix 2). We supplemented the electronic searches with a manual search of the reference lists. No language restrictions were applied.

A two stage process was used to select the reviews. Firstly, two reviewers (JA, JS) independently screened the titles and abstracts to identify eligible reviews and then retrieved and assessed the full texts of relevant citations. Disagreements were resolved through discussion with a third reviewer (JZ). We included systematic reviews of randomised trials and cohort, case-control, or cross sectional studies that reported the effects of maternal paracetamol use during pregnancy on risk of autism and ADHD in offspring. We excluded narrative reviews, reviews of studies that focused solely on animal research, case series, conference abstracts, and studies that did not report outcomes related to autism or ADHD. When reviews contained overlapping primary studies, we documented the overlap.

Quality assessment

Two independent reviewers (MNP and HMB) assessed the methodological quality of the included reviews using AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews).24 Disagreements were resolved by discussion with a third reviewer (JZ). The tool evaluates the following domains, seven of these (marked with an asterisk) were considered critical: *a priori design or protocol registration, *comprehensive literature search strategy, use of publication status (eg, inclusion of grey literature) as an inclusion criterion, duplicate study selection and data extraction, *list and justification of excluded studies, characteristics of the included primary studies, *assessment and documentation of the quality or risk of bias of included studies, *appropriate use of study quality in interpreting and formulating conclusions, *appropriate statistical methods for combining study findings, *assessment of the likelihood of publication bias, and disclosure of conflicts of interest by the review authors. Following the proposed framework, we categorised our overall confidence in the results of the reviews as high (no critical weaknesses and at most one non-critical weakness), moderate (no critical weaknesses but more than one non-critical weakness), low (one critical weakness), or critically low (more than one critical weakness).

Data extraction and analysis

We extracted data independently and in duplicate (SS and JA) using a piloted standardised form. Information was extracted on review characteristics (year, review type, number and design of included studies, population characteristics), exposure (timing, duration, method of ascertainment of paracetamol use), type of outcomes (autism, ADHD) and their definition, the confounders considered, risk of bias assessment of the primary studies and the tools used, methods of synthesis, effect estimates and confidence intervals of the included primary studies, and the overall and subgroup findings. When reviews undertook meta-analysis, we extracted data on effect estimates, heterogeneity measures, and any publication bias.

A narrative synthesis of the included systematic reviews was undertaken. To address overlap, we constructed a citation matrix to map primary studies included in each systematic review and quantified the overlap using the corrected covered area method.25 The degree of overlap was categorised as slight (0-5%), moderate (6-10%), high (11-15%), and very high (>15%). To avoid overrepresentation of individual primary studies, we interpreted the findings with consideration of the extent of duplication. For each outcome we reported the pooled effect estimates with 95% confidence intervals as provided in the meta-analyses. We extracted information on the characteristics of the primary studies included in the reviews, their adjustment for key confounders such as maternal characteristics, indications for paracetamol use, familial genetic and environmental factors, and unmeasured confounding, and the methods used to ascertain autism and ADHD outcomes in offspring, such as clinician diagnosis, medical records, or validated parent completed or teacher completed questionnaires.

Patient and public involvement

We involved a carer of a child and grandchild with autism and a woman with lived experience of ADHD. Both provided input into our research question, reviewed the manuscript, and helped interpret the findings. They shared their lived experience of having a diagnosis of ADHD and how it affects many members of the family. They felt that recognising the strong familial and genetic links can reduce misplaced blame and reassure families that neurodivergence in their children is not caused by anything the mother did during pregnancy. The contributors highlighted the need for a comprehensive evidence base for paracetamol use during pregnancy and clear dissemination of the findings.

Results

From 663 citations, we included nine systematic reviews161726272829303132 that reported the findings from 40 primary studies (37 prospective cohorts, two case-control studies,3334 and one ecological study35); four were meta-analyses.17273031Figure 1 provides the flow chart of the review identification process.

Characteristics of the included reviews

All reviews were published in the past 10 years and focused on maternal paracetamol intake throughout pregnancy, with one including both antenatal and postnatal use.32 Seven reviews included only cohort studies26272829303132 and two included cohort and case-control studies.1617 Two reviews included studies with inappropriate designs, such as multivariate predictive model and ecological study, to assess the exposure-outcome association.1632 One review included a study that assessed maternal genetic ADHD risk and paracetamol use in pregnancy.16Table 1 and supplementary appendix 3 provide the characteristics of the reviews, criteria for the inclusion of primary studies, the tools used for quality assessment, and the outcomes reported. Of the 40 studies included in the reviews, six reported on autism and 17 on ADHD. Supplementary appendix 4 provides the characteristics of the primary studies included in the reviews. Only one review, a narrative synthesis, included studies (n=2) that adjusted for shared familial factors and unmeasured confounding using sibling controlled analysis for autism (one study) and ADHD (two studies) outcomes in offspring.16 The two sibling controlled studies involved populations from Sweden (Ahlqvist et al)36 and Norway (Gustavson et al)37 and provided estimates by dose and duration of paracetamol use (see supplementary appendix 5).3637 Supplementary appendix 6 provides the list of the excluded systematic reviews and the rationale for exclusion.

Table 1

Characteristics of systematic reviews included in the umbrella review on maternal paracetamol (acetaminophen) use during pregnancy and risk of ASD and ADHD in offspring

Quality of the included reviews

The methodological quality of the nine included systematic reviews revealed substantial weaknesses across several critical domains (fig 2). Most reviews lacked a previously registered protocol (item 2), did not provide a comprehensive literature search strategy (item 4), and did not present a list of excluded studies with justifications (item 7). Furthermore, the assessment and consideration of risk of bias in primary studies were frequently absent or partially present. None of the systematic reviews used the recommended tool to assess the risk of bias of non-randomised trials (either ROBINS-E or ROBINS-I) (item 9). Appropriate statistical methods for meta-analysis were rarely applied. The meta-analysis adjusted for confounding effect estimates in only one review (item 11). The impact of risk of bias on the interpretation of results was addressed only in three systematic reviews (item 13). Likewise, only one review adequately investigated publication bias when quantitative synthesis was undertaken (item 15). Owing to these issues in multiple critical domains, the overall confidence in the results was rated as critically low in seven systematic reviews17262728293031 and low in two systematic reviews.1632 The corrected covered area was 23%, indicating a very high overlap among the reviews, with the nine reviews mostly based on the same primary studies (see supplementary appendix 7).

Fig 2

Methodological quality of reviews. Overall confidence in the results of the review are classified: High: Zero or one non-critical weakness: the systematic review provides an accurate and comprehensive summary of the results of the available studies that address the question of interest. Moderate: More than one non-critical weakness: the systematic review has more than one weakness, but no critical flaws. It may provide an accurate summary of the results from the available studies included in the review. Low: One critical flaw with or without non-critical weaknesses: the review has a critical flaw and may not provide an accurate and comprehensive summary of the available studies that address the question of interest. Critically low: More than one critical flaw with or without non-critical weaknesses: the review has more than one critical flaw and should not be relied on to provide an accurate and comprehensive summary of the available studies. Notes: Item 1: The current study rated this as “no” when the review did not include a section that explicitly specified the components of the PICO question. If these components were not stated in the review but were available in the published protocol, the current study rated this item as “yes.” Item 3: The current study rated this item as “no” when the review did not justify the choice of study design(s). If the review merely listed the types of studies to be included, or stated that all types of studies were eligible, it was also rated as “no.” Item 9: Given that the ROBINS-I and ROBINS-E tools are the standard for evaluating risk of bias in non-randomised studies, the use of alternative instruments was rated as “partial yes,” since they do not provide the same level of methodological rigour and comprehensiveness. Item 11: Since one of the conditions for scoring this item as “yes” is either that adjusted data were included in the pooled analysis or that the use of raw data was justified when adjusted data were unavailable, the current study rated this item as “no” when these conditions were not met. Masarwa 2020 is an update of Masarwa 2018. This review focused on unmeasured confounding and provided limited details on the review methodology, stating that the same methods as the previous review were followed. *Critical domains. AMSTAR-2=A MeaSurement Tool to Assess systematic Reviews 2; MA=meta-analysis; PICO=population, intervention, comparison and outcome; RoB=risk of bias; ROBINS-E=Risk Of Bias In Non-randomised Studies-of Exposure; ROBINS-I=Risk Of Bias In Non-randomised Studies-of Interventions

• Download figure
• Open in new tab
• Download powerpoint

Effects of maternal paracetamol use on autism and/or ADHD in offspring

All reviews reported a positive association between maternal paracetamol use in pregnancy and adverse neurodevelopmental outcomes in offspring. The conclusions of seven of the nine reviews warned against interpreting a causal link between maternal paracetamol use and autism or ADHD, or both in offspring, citing lack of data, bias in the primary studies, and unmeasured or inadequately controlled confounders (table 1). The four reviews that performtavson et al were based on nationwide registries that included almost all births, and Okubo et al directly assessed for selection bias using inverse probability weights and bounding factors and found minimal impact on the findings.363746 In the study by Gustavson et al,37 out of the 29 090 siblings initially identified, 2477 were excluded owing to missing information on exposure and 5165 for missing information on covariates, which totalled about 25% of the sibling sample. The main analyses relied on complete cases. However, multiple imputation yielded estimates similar to the complete case results, suggesting that any bias from missing covariates would likely not materially change conclusions.

One additional earlier sibling study, by Brandlistuen et al, from the same Norwegian cohort on maternal paracetamol use in pregnancy and parent reported externalising symptoms in children, reported poorer child development at three years and that associations appeared stronger in their sibling analysis.47 This conflicts with the later study by Gustavson et al, which used the same cohort with longer follow-up and registry based diagnoses of ADHD and autism and showed attenuation in sibling analyses. Several factors can explain the divergence: Brandlistuen et al studied early developmental traits reported by mothers, not clinical diagnoses of ADHD; they used an earlier, less mature dataset with fewer siblings and shorter follow-up; and the number of discordant sibling pairs was small, which makes estimates unstable.47

Implications for clinical practice and policy

Our review shows the lack of robust evidence linking paracetamol use in pregnancy and autism and ADHD in offspring. Regulatory bodies, clinicians, pregnant women, parents, and those affected by autism and ADHD should be informed about the poor quality of the existing reviews and the likelihood that positive associations reported in studies were driven by familial confounding. Given that alternative classes of drugs for relief of pain and fever, such as non-steroidal anti-inflammatory drugs, are known to adversely affect the fetal vascular system and can cause complications such as oligohydramnios and premature closure of the ductus arteriosus,484950 and considering the harmful effects of pyrexia on pregnancy, women should be advised to take paracetamol when needed to treat pain and pyrexia in pregnancy.51

To date, no well established molecular mechanisms link exposure to paracetamol with autism or ADHD in childhood. A quantitative review of animal studies found no consistent evidence that developmental exposure to paracetamol at therapeutic or non-toxic doses results in neurodevelopmental harm.52 Various hypotheses based on animal, in vitro, and in silico work have proposed that paracetamol could influence fetal brain development through oxidative stress53; mitochondrial effects54; prostaglandin, endocannabinoid, or TRPV1 signalling55; or epigenetic changes.56 But it is important to note that data from human studies to support any of these putative mechanisms is lacking. Such a lack of evidence around medicine use during pregnancy remains a critical and longstanding problem resulting from the historical and ongoing underinvestment in women’s health research, particularly in pregnancy, perpetuating an evidence gap.21

Implications for research

In the future, studies reporting the effects of paracetamol use in pregnancy on neurodevelopment in children should ensure both reliable assessment of exposure and rigorous ascertainment of outcomes, address bias due to confounding that includes indication bias, and prioritise adjustment for genetic and shared environmental factors, preferably through sibling cohorts. Lastly, studies should triangulate results across complementary analyses, including population models, sibling comparisons, negative controls, and sensitivity analyses, to minimise biases inherent to any single approach.

Conclusion

Reviews have reported an association between maternal paracetamol use during pregnancy and autism or ADHD in offspring, but quality was low. The current evidence base is insufficient to definitively link in utero exposure to paracetamol with autism and ADHD in childhood. High quality studies that control for familial and unmeasured confounders can help improve evidence on the timing and duration of paracetamol exposure, and for other child neurodevelopmental outcomes.

What is already known on this topic

Paracetamol (acetaminophen) is the recommended treatment for pain and fever in pregnancy and is considered safe by regulatory agencies worldwide

Systematic reviews and primary studies vary in their reporting on maternal paracetamol use during pregnancy and risk of autism spectrum disorder (autism) and attention deficit/hyperactivity disorder (ADHD) in offspring

Familial factors, maternal health and behaviour, and socioeconomic environment influence the neurodevelopmental outcomes of babies

What this study adds

Confidence in the findings of published systematic reviews on maternal paracetamol use during pregnancy and risk of autism and ADHD in offspring, with a very high overlap of primary studies, is low to critically low

Existing evidence does not show a clear link between in utero exposure to paracetamol and autism and ADHD in offspring

Any apparent effect observed after in utero exposure to paracetamol on autism and ADHD in childhood might be driven by familial genetic and environmental factors and unmeasured confounders

Ethics statements

Ethical approval

Not required.

Data availability statement

All data relevant to the study is included in the article or uploaded as supplementary information.

Acknowledgments

We thank CW and JP, two public and patient partnership members who provided their valuable lived experiences and input into the study, and Alexander Davies and Caroline Dale at the University of Liverpool for their support during preparation of this manuscript.

Footnotes

Contributors: JS, JA, and SS are joint first authors and contributed equally to this work. ST and JZ are joint last authors and contributed equally to this work. JS, JA, SS, HN, FN, MNP, and HMB conducted study selection, data extraction, and analysis and wrote the manuscript. ST and JZ designed the study, supervised the project, and revised the manuscript. MNP and HMB assisted with detailed statistical analysis. All authors reviewed and approved the final version of the manuscript. ST is the guarantor. The corresponding author (ST) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: ST is a senior investigator for the National Institute for Health and Care Research (NIHR). SS is funded by the NIHR Midlands Patient Safety Research Collaboration. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. HMB is supported by the Instituto de Salud Carlos III through a Río Hortega contract (CM24/00152), co-funded by European Social Fund Plus.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Transparency: The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: The findings of this study will be disseminated to the public through institutional press releases, academic and public facing blogs, and social media platforms to maximise accessibility and engagement. The results will also be shared with relevant patient and public involvement networks and organisations focused on maternal and child health. All outputs will be published open access to ensure broad availability.

Provenance and peer review: Not commissioned; externally peer reviewed.